บทความที่มีข้อกำหนดการเข้าถึงสาธารณะ - Jacqueline Cloosดูข้อมูลเพิ่มเติม
ไม่มีให้ใช้งานในทุกที่: 3
Molecular basis of resistance to proteasome inhibitors in hematological malignancies
D Niewerth, G Jansen, YG Assaraf, S Zweegman, GJL Kaspers, J Cloos
Drug resistance updates 18, 18-35, 2015
ข้อกำหนด: Royal Netherlands Academy of Arts and Sciences
Clinical relevance of molecular aberrations in paediatric acute myeloid leukaemia at first relapse
C Bachas, GJ Schuurhuis, D Reinhardt, U Creutzig, ZJ Kwidama, ...
British journal of haematology 166 (6), 902-910, 2014
ข้อกำหนด: Dutch Cancer Society
Relevance of leukemic stem cells in acute myeloid leukemia: heterogeneity and influence on disease monitoring, prognosis and treatment design
R Wouters, D Cucchi, GJL Kaspers, GJ Schuurhuis, J Cloos
Expert Review of Hematology 7 (6), 791-805, 2014
ข้อกำหนด: Dutch Cancer Society
มีให้ใช้งานในบางที่: 66
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
GJ Schuurhuis, M Heuser, S Freeman, MC Béné, F Buccisano, J Cloos, ...
Blood, The Journal of the American Society of Hematology 131 (12), 1275-1291, 2018
ข้อกำหนด: US National Institutes of Health, German Research Foundation, Cancer …
Molecular minimal residual disease in acute myeloid leukemia
M Jongen-Lavrencic, T Grob, D Hanekamp, FG Kavelaars, A Al Hinai, ...
New England Journal of Medicine 378 (13), 1189-1199, 2018
ข้อกำหนด: Netherlands Organisation for Scientific Research, Netherlands Organisation …
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
M Heuser, SD Freeman, GJ Ossenkoppele, F Buccisano, CS Hourigan, ...
Blood, The Journal of the American Society of Hematology 138 (26), 2753-2767, 2021
ข้อกำหนด: US National Institutes of Health, Cancer Research UK
Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia
K De Keersmaecker, ZK Atak, N Li, C Vicente, S Patchett, T Girardi, ...
Nature genetics 45 (2), 186-190, 2013
ข้อกำหนด: US National Institutes of Health, Research Foundation (Flanders)
In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma
SE Mir, PCDW Hamer, PM Krawczyk, L Balaj, A Claes, JM Niers, ...
Cancer cell 18 (3), 244-257, 2010
ข้อกำหนด: US National Institutes of Health
miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis
M Smits, J Nilsson, SE Mir, PM van der Stoop, E Hulleman, JM Niers, ...
Oncotarget 1 (8), 710, 2011
ข้อกำหนด: US National Institutes of Health, Swedish Research Council
Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells
NE Franke, D Niewerth, YG Assaraf, J van Meerloo, K Vojtekova, ...
Leukemia 26 (4), 757-768, 2012
ข้อกำหนด: Royal Netherlands Academy of Arts and Sciences
Comprehensive analysis of transcriptome variation uncovers known and novel driver events in T-cell acute lymphoblastic leukemia
Z Kalender Atak, V Gianfelici, G Hulselmans, K De Keersmaecker, ...
PLoS genetics 9 (12), e1003997, 2013
ข้อกำหนด: Research Foundation (Flanders), European Commission
Bortezomib resistance in multiple myeloma is associated with increased serine synthesis
EA Zaal, W Wu, G Jansen, S Zweegman, J Cloos, CR Berkers
Cancer & metabolism 5, 1-12, 2017
ข้อกำหนด: Netherlands Organisation for Scientific Research
Leukemic stem cells: identification and clinical application
D Hanekamp, J Cloos, GJ Schuurhuis
International journal of hematology 105, 549-557, 2017
ข้อกำหนด: Dutch Cancer Society
Down-regulation of miR-101 in endothelial cells promotes blood vessel formation through reduced repression of EZH2
M Smits, SE Mir, RJA Nilsson, PM van der Stoop, JM Niers, VE Marquez, ...
PloS one 6 (1), e16282, 2011
ข้อกำหนด: US National Institutes of Health, Swedish Research Council
Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1
J Fang, G Rhyasen, L Bolanos, C Rasch, M Varney, M Wunderlich, ...
Blood, The Journal of the American Society of Hematology 120 (4), 858-867, 2012
ข้อกำหนด: US National Institutes of Health
The role of minor subpopulations within the leukemic blast compartment of AML patients at initial diagnosis in the development of relapse
C Bachas, GJ Schuurhuis, YG Assaraf, ZJ Kwidama, A Kelder, F Wouters, ...
Leukemia 26 (6), 1313-1320, 2012
ข้อกำหนด: Royal Netherlands Academy of Arts and Sciences
Clinical Impact of Additional Cytogenetic Aberrations, cKIT and RAS Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International …
K Klein, G Kaspers, CJ Harrison, HB Beverloo, A Reedijk, M Bongers, ...
Journal of Clinical Oncology 33 (36), 4247-4258, 2015
ข้อกำหนด: US National Institutes of Health
Methotrexate resistance in relation to treatment outcome in childhood acute lymphoblastic leukemia
A Wojtuszkiewicz, GJ Peters, NL van Woerden, B Dubbelman, ...
Journal of hematology & oncology 8, 1-13, 2015
ข้อกำหนด: Royal Netherlands Academy of Arts and Sciences
Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer
LHAM de Wilt, G Jansen, YG Assaraf, J van Meerloo, J Cloos, ...
Biochemical pharmacology 83 (2), 207-217, 2012
ข้อกำหนด: Royal Netherlands Academy of Arts and Sciences
Effect of noncompetitive proteasome inhibition on bortezomib resistance
X Li, TE Wood, R Sprangers, G Jansen, NE Franke, X Mao, X Wang, ...
JNCI: Journal of the National Cancer Institute 102 (14), 1069-1082, 2010
ข้อกำหนด: Ontario Institute for Cancer Research
แหล่งที่มาและข้อมูลกองทุนดำเนินการโดยโปรแกรมคอมพิวเตอร์โดยอัตโนมัติ